Want to see CELU full AI Analyst Report?
Top Page
Celularity
(NASDAQ:CELU)
Select Model
Select Model
Rating:42Neutral
Price Target:
$0.67
▼(-10.40% Downside)
Action:Reiterated
Date:08/09/26
The score is primarily constrained by weak financial performance (ongoing losses, recent revenue decline, and negative equity) and bearish technicals (price below key moving averages with negative MACD). Valuation provides limited support due to negative earnings and no dividend. Corporate events further pressure the outlook due to Nasdaq compliance risks and signs of near-term financing strain.
Positive Factors
Proprietary allogeneic platform
Celularity’s core placental-derived allogeneic cell and biomaterial platform is a durable competitive asset: it supports multiple therapeutic modalities (NK, T-cell, regenerative biomaterials) and internal manufacturing/sourcing advantages, enabling reuse across oncology and regenerative indications and lowering single-product binary risk.
Negative Factors
Negative equity / high leverage
Negative shareholders’ equity and sustained debt materially impair financial flexibility. This structural balance‑sheet weakness raises refinancing and dilution risk, constrains negotiating leverage with partners or lenders, and can limit the firm’s ability to fund clinical programs without dilutive or costly capital solutions.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary allogeneic platform
Celularity’s core placental-derived allogeneic cell and biomaterial platform is a durable competitive asset: it supports multiple therapeutic modalities (NK, T-cell, regenerative biomaterials) and internal manufacturing/sourcing advantages, enabling reuse across oncology and regenerative indications and lowering single-product binary risk.
Read all positive factors
Celularity (CELU) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$19.97M
Dividend YieldN/A
Average Volume (3M)206.82K
Price to Earnings (P/E)―
Beta (1Y)3.17
Revenue Growth-51.03%
EPS Growth-35.20%
CountryUS
Employees115
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.69
Shares Outstanding28,945,961
10 Day Avg. Volume277,262
30 Day Avg. Volume206,824
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.75
Price to Sales (P/S)1.07
P/FCF Ratio-2.14
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.75
Revenue Forecast (FY)$44.00M
Celularity Business Overview & Revenue Model
Company Description
Celularity Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering "off-the-shelf" allogeneic cell therapies, which are developed from placental sources. These innovative treatments are designed to combat a range of serious condi...
How the Company Makes Money
Celularity’s publicly described revenue model is based on (1) advancing its placental-derived allogeneic cell therapy pipeline toward commercialization and (2) monetizing its platforms through collaborations and other commercial arrangements. Spec...
Celularity Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
22
Negative
Cash Flow
28
Negative
| Breakdown | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 26.55M | 54.22M | 22.77M | 17.98M | 21.34M |
| Gross Profit | 20.19M | 39.23M | 6.75M | -1.69M | 11.68M |
| EBITDA | -77.66M | -43.71M | -183.95M | -138.83M | -88.11M |
| Net Income | -91.80M | -57.89M | -196.29M | 14.19M | -100.12M |
Balance Sheet | |||||
| Total Assets | 107.33M | 132.68M | 143.89M | 401.07M | 414.13M |
| Cash, Cash Equivalents and Short-Term Investments | 6.17M | 738.00K | 227.00K | 13.97M | 37.24M |
| Total Debt | 40.90M | 68.84M | 65.42M | 65.59M | 31.14M |
| Total Liabilities | 145.39M | 123.84M | 102.93M | 202.16M | 314.71M |
| Stockholders Equity | -38.06M | 8.84M | 40.96M | 198.90M | 99.42M |
Cash Flow | |||||
| Free Cash Flow | -13.25M | -6.56M | -42.73M | -143.11M | -116.30M |
| Operating Cash Flow | -13.25M | -6.40M | -38.69M | -137.88M | -110.10M |
| Investing Cash Flow | 0.00 | 514.00K | -4.05M | -5.24M | -5.90M |
| Financing Cash Flow | 18.65M | 6.70M | 24.09M | 119.84M | 98.56M |
Celularity Technical Analysis
Negative
0.75
Price Trends
0.73
Negative
0.91
Negative
1.18
Negative
Market Momentum
-0.02
Negative
46.95
Neutral
49.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CELU, the sentiment is Negative. The current price of 0.75 is above the 20-day moving average (MA) of 0.72, above the 50-day MA of 0.73, and below the 200-day MA of 1.18, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 46.95 is Neutral, neither overbought nor oversold. The STOCH value of 49.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CELU.
Celularity Risk Analysis
Celularity disclosed 76 risk factors in its most recent earnings report. Celularity reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Celularity Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $751.72M | -14.35 | -43.57% | ― | -66.63% | 57.89% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $7.39M | -0.21 | -767.07% | ― | ― | 22.10% | |
42 Neutral | $19.97M | -0.19 | 411.46% | ― | -51.03% | -35.20% | |
42 Neutral | $33.94M | -1.81 | -198.35% | ― | ― | 21.67% |
* Healthcare Sector Average
CELU
Celularity
0.70
-2.79
-80.03%
LTRN
Lantern Pharma
2.63
-1.94
-42.45%
STTK
Shattuck Labs
7.32
6.32
632.00%
FBLG
FibroBiologics, Inc.
1.15
-10.32
-89.97%
Celularity Corporate Events
Business Operations and StrategyExecutive/Board Changes
Celularity Announces Sudden Exit of Chief Commercial Officer
Negative
Aug 7, 2026
On August 5, 2026, Celularity Inc. terminated the employment of Rick Gonzalez, who had been serving as the company’s Chief Commercial Officer, effective immediately. The abrupt departure of a key commercial executive may signal a shift in Ce...
Delistings and Listing ChangesRegulatory Filings and Compliance
Celularity Faces Nasdaq Listing Compliance Bid-Price Warning
Negative
Jul 29, 2026
On July 23, 2026, Celularity Inc. received notice from Nasdaq that its Class A common stock no longer meets the exchange’s minimum bid price requirement, after trading below $1.00 per share for 30 consecutive business days. The stock continu...
Executive/Board ChangesPrivate Placements and Financing
Celularity Secures Insider-Backed Short-Term Loan Facility
Negative
Jun 30, 2026
On June 29, 2026, Celularity entered into a secured $1 million short‑term loan agreement with the Philip Daniele Barach Family Trust, a related party lender affiliated with a significant shareholder, bearing 4.0% annual interest and maturin...
Business Operations and StrategyExecutive/Board Changes
Celularity Strengthens Leadership With New Executive Appointments
Positive
Jun 25, 2026
On June 19, 2026, Celularity’s board appointed entrepreneur and biotechnology-focused executive Steven N. Gordon as chief operating and administrative officer, elevating him from his prior role as EVP, Business Affairs and also naming him to...
Delistings and Listing ChangesRegulatory Filings and Compliance
Celularity Faces Nasdaq Listing Compliance Risk After Notice
Negative
Jun 12, 2026
On June 9, 2026, Celularity Inc. disclosed that it received a notice from Nasdaq stating that the company’s market value of listed securities had fallen below the $35 million minimum required for continued listing on the Nasdaq Capital Marke...
Business Operations and StrategyExecutive/Board Changes
Celularity Appoints Rick Gonzalez as Chief Commercial Officer
Positive
Jun 3, 2026
On May 29, 2026, Celularity appointed industry veteran Rick Gonzalez as Chief Commercial Officer to lead global commercial strategy for its placental-derived regenerative medicine portfolio, including cenplacel-L and the Lifebank cellular banking ...
Business Operations and StrategyLegal ProceedingsPrivate Placements and Financing
Celularity Enters Settlement, Restructuring Financing Obligations
Neutral
May 28, 2026
On May 21, 2026, Celularity Inc. entered into a Settlement Agreement with Helena Global Investment Opportunities 1 Ltd., resolving disputes that arose after Helena exchanged its Series A Convertible Preferred Stock for a convertible promissory not...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.